Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × asciminib × Breast × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3 Lymphoid 2 Other solid neoplasm 1 Myeloid 1 Gastrointestinal 1 Breast 1

Conditions

HER2+ Metastatic Breast Cancer 1

Interventions

Trastuzumab 65 Paclitaxel 60 Cyclophosphamide 48 pembrolizumab 47 Carboplatin 39 Fulvestrant 37 Capecitabine 33 Docetaxel 29 Letrozole 23 Doxorubicin 21 palbociclib 19 pertuzumab 17 Nivolumab 17 eribulin 16 durvalumab 15 abemaciclib 15 Albumin-Bound Paclitaxel 15 130-nm albumin-bound paclitaxel 15 ribociclib 14 Gemcitabine 14 sacituzumab govitecan 13 Taxes 12 Lapatinib 12 Everolimus 12 Bevacizumab 12 olaparib 11 fludarabine 11 Vinorelbine 11 Filgrastim 11 exemestane 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07136428 2025-12-19

ASCENdANT

Duke University

Phase 1/2 Not yet recruiting

HER2+ Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡